Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Isolation of an escape-resistant SARS-CoV-2 neutralizing nanobody from a novel synthetic nanobody library
Dmitri Dormeshkin, Michail Shapira, Simon Dubovik, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 11

Showing 11 citing articles:

Nanoscale warriors against viral invaders: a comprehensive review of Nanobodies as potential antiviral therapeutics
Vaishali Verma, N. D. Sinha, A. Raja
mAbs (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 1
Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses
Yang Yang, Fang Li, Lanying Du
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 9
The Use of Heterologous Antigens for Biopanning Enables the Selection of Broadly Neutralizing Nanobodies Against SARS-CoV-2
V. S. Aripov, Anna V. Zaykovskaya, Ludmila V. Mechetina, et al.
Antibodies (2025) Vol. 14, Iss. 1, pp. 23-23
Open Access
Promises and challenges of single-domain antibodies to control influenza
Arne Matthys, Xavier Saelens
Antiviral Research (2024) Vol. 222, pp. 105807-105807
Closed Access | Times Cited: 3
CAR-T Cell Therapy for Classical Hodgkin Lymphoma
Mikalai Katsin, Dmitri Dormeshkin, Alexander Meleshko, et al.
HemaSphere (2023) Vol. 7, Iss. 12, pp. e971-e971
Open Access | Times Cited: 8
Status and Developing Strategies for Neutralizing Monoclonal Antibody Therapy in the Omicron Era of COVID-19
Zuning Ren, Chenguang Shen, Jie Peng
Viruses (2023) Vol. 15, Iss. 6, pp. 1297-1297
Open Access | Times Cited: 6
Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1
Jiali Wang, Bingjie Shi, Hanyi Chen, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 417-417
Open Access | Times Cited: 2
Applications of nanobodies in the prevention, detection, and treatment of the evolving SARS-CoV-2
Wenyi Wang, Yue Hu, Bohan Li, et al.
Biochemical Pharmacology (2022) Vol. 208, pp. 115401-115401
Open Access | Times Cited: 10
Design and Immunogenicity of SARS-CoV-2 DNA Vaccine Encoding RBD-PVXCP Fusion Protein
Dmitri Dormeshkin, Mikalai Katsin, Maria Stegantseva, et al.
Vaccines (2023) Vol. 11, Iss. 6, pp. 1014-1014
Open Access | Times Cited: 2
Bringing cell therapy to tumors: considerations for optimal CAR binder design
Richard Smith
Antibody Therapeutics (2023) Vol. 6, Iss. 4, pp. 225-239
Open Access | Times Cited: 1
Design and Immunogenicity of SARS-CoV-2 DNA vaccine encoding RBD-PVXCP fusion protein
Dmitri Dormeshkin, Mikalai Katsin, Maria Stegantseva, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top